Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events

被引：0
|
作者：
Agata Ptaszynska
Kristina M. Johnsson
Shamik J. Parikh
Tjerk W. A. de Bruin
Anne Marie Apanovitch
James F. List
机构：
[1] Bristol-Myers Squibb,
[2] Global Clinical Research,undefined
[3] Research and Development,undefined
[4] AstraZeneca,undefined
[5] Research and Development,undefined
[6] AstraZeneca,undefined
[7] Global Medicines Development,undefined
[8] Bristol-Myers Squibb,undefined
[9] Global Biometric Sciences,undefined
[10] Research and Development,undefined
来源：
Drug Safety | 2014年 / 37卷
关键词：
Placebo Group; Metformin; Uric Acid Level; Glipizide; Urinary Stone;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：815 / 829
页数：14
相关论文
共 50 条
  • [21] Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
    Williams-Herman, Debora
    Engel, Samuel S.
    Round, Elizabeth
    Johnson, Jeremy
    Golm, Gregory T.
    Guo, Hua
    Musser, Bret J.
    Davies, Michael J.
    Kaufman, Keith D.
    Goldstein, Barry J.
    BMC ENDOCRINE DISORDERS, 2010, 10
  • [22] Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus
    Ona Kinduryte Schorling
    Douglas Clark
    Isabella Zwiener
    Stefan Kaspers
    Jisoo Lee
    Hristo Iliev
    Advances in Therapy, 2020, 37 : 3463 - 3484
  • [23] Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
    Samuel S Engel
    Gregory T Golm
    Deborah Shapiro
    Michael J Davies
    Keith D Kaufman
    Barry J Goldstein
    Cardiovascular Diabetology, 12
  • [24] Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus
    Kinduryte Schorling, Ona
    Clark, Douglas
    Zwiener, Isabella
    Kaspers, Stefan
    Lee, Jisoo
    Iliev, Hristo
    ADVANCES IN THERAPY, 2020, 37 (08) : 3463 - 3484
  • [25] Safety Profiles of Sitagliptin and Metformin as Monotherapy for Type 2 Diabetes: A Pooled Analysis
    Katzeff, Harvey L.
    Engel, Samuel S.
    Wang, Hongwei
    Langdon, Ronald B.
    Williams-Herman, Debora
    Kaufman, Keith D.
    Goldstein, Barry J.
    DIABETES, 2010, 59 : A570 - A571
  • [26] Efficacy and Safety of Saxagliptin as Monotherapy in Patients with Type 2 Diabetes: A Pooled Analysis
    Hirshberg, Boaz
    Bryzinski, Brian
    Xu, John
    Monyak, John
    Iqbal, Nayyar
    DIABETES, 2014, 63 : A610 - A610
  • [27] A Pooled Analysis of the Efficacy and Safety of Saxagliptin as Monotherapy in Patients with Type 2 Diabetes
    Hirshberg, Boaz
    Bryzinski, Brian
    Xu, John
    Iqbal, Nayyar
    JOURNAL OF DIABETES & METABOLISM, 2015, 6 (04)
  • [28] Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
    Engel, Samuel S.
    Golm, Gregory T.
    Shapiro, Deborah
    Davies, Michael J.
    Kaufman, Keith D.
    Goldstein, Barry J.
    CARDIOVASCULAR DIABETOLOGY, 2013, 12
  • [29] Cardiovascular (CV) safety of linagliptin in patients with type 2 diabetes: a pooled comprehensive analysis of prospectively adjudicated CV events in phase 3 studies
    Johansen, O.
    Neubacher, D.
    Seck, T.
    Patel, S.
    Woerle, H. -J.
    DIABETOLOGIA, 2013, 56 : S52 - S52
  • [30] Safety and efficacy of linagliptin in patients with type 2 diabetes mellitus and coronary artery disease: Analysis of pooled events from 19 clinical trials
    Lehrke, Michael
    Leiter, Lawrence A.
    Hehnke, Uwe
    Thiemann, Sandra
    Bhandari, Amit
    Meinicke, Thomas
    Johansen, Odd Erik
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2016, 30 (07) : 1378 - 1384
12345